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Abstract 
Background: Elevated lactate concentration has been associated with increased mortality after out‑of‑hospital 
cardiac arrest (CA). We investigated the variables associated with high blood lactate concentrations and explored the 
relationship between blood lactate and neurological outcome in this setting.
Methods: This was a retrospective analysis of an institutional database that included all adult (> 18 years) patients 
admitted to a multidisciplinary Department of Intensive Care between January 2009 and January 2013 after resusci‑
tation from CA. Blood lactate concentrations were collected at hospital admission and 6, 12, 24 and 48 h thereafter. 
Neurological outcome was evaluated 3 months post‑CA using the Cerebral Performance Category (CPC) score: a CPC 
of 3–5 was used to define a poor outcome.
Results: Of the 236 patients included, 162 (69%) had a poor outcome. On admission, median lactate concentrations 
(5.3[2.9–9.0] vs. 2.5[1.5–5.5], p < 0.001) and cardiovascular sequential organ failure assessment (cSOFA) score (3[0–4] 
vs. 0[0–3], p = 0.003) were higher in patients with poor than in those with favourable outcomes. Lactate concentra‑
tions were higher in patients with poor outcomes at all time points. Lactate concentrations were similar in patients 
with out‑of‑hospital and in‑hospital CA at all time points. After adjustment, high admission lactate was independently 
associated with a poor neurological outcome (OR 1.18, 95% CI 1.08–1.30; p < 0.001). In multivariable analysis, use of 
vasopressors and high  PaO2 on admission, longer time to return of spontaneous circulation and altered renal function 
were associated with high admission lactate concentrations.
Conclusions: High lactate concentrations on admission were an independent predictor of poor neurological recov‑
ery post‑CA, but the time course was not related to outcome. Prolonged resuscitation, use of vasopressors, high  PaO2 
and altered renal function were predictors of high lactate concentrations.
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Background
Every year, between 37 and 100 per 100,000 inhabit-
ants have an out-of-hospital cardiac arrest (OHCA) in 
Western countries, with approximately 10% surviving to 
hospital discharge [1, 2]. Despite the more immediate 
availability of advanced life support, survival to hospital 
discharge after in-hospital CA (IHCA) does not exceed 
15–20% [3, 4]. High-quality cardiopulmonary resuscita-
tion (CPR) and early defibrillation, when indicated, are 
essential to achieve a good outcome [5]. However, when 
return of spontaneous circulation (ROSC) is achieved, 
there is still uncertainty about which therapeutic inter-
ventions most effectively improve the survival and neuro-
logical recovery of these patients.
Blood lactate concentrations may represent a marker 
of cellular hypoxia after CA. Patients with high blood 
lactate concentrations on admission after CA are more 
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likely to die than those with lower concentrations [6, 7]. 
In this setting, blood lactate concentrations may be con-
sidered as a marker of prolonged hypoperfusion or poor 
resuscitation. Other studies have also suggested that a 
faster decrease in lactate concentrations during the early 
hours after resuscitation may be correlated with better 
survival [8–10]. This decrease may reflect more rapid 
haemodynamic stabilization with therapy. Nevertheless, 
these studies included only patients with OHCA and the 
importance of lactate concentrations in IHCA survivors 
remains uncertain. As the underlying causes and man-
agement of OHCA and IHCA are different (e.g. cardiac 
vs. non-cardiac causes, different delays for interventions, 
different types of initial rhythm, presence of pre-existing 
medical conditions), the absolute initial lactate concen-
trations, as well as changes in lactate concentrations over 
time, may vary accordingly and potentially have different 
prognostic value. Few data are available on the impact of 
lactate concentrations and their evolution on neurologi-
cal recovery, and the variables associated with high blood 
lactate after CA have not been well studied [7].
The aims of this study were, therefore, to: (a) evaluate 
whether any lactate-related variable (i.e. admission value, 
peak lactate, decreased concentration over time, area 
under the curve of concentrations over 48 h) was associ-
ated with neurological outcome; (b) identify the variables 
associated with high lactate concentrations after CA; 
and (c) explore the differences in lactate concentrations 
between IHCA and OHCA.
Methods
Study population
We retrospectively reviewed prospectively collected 
data from all adult (> 18 years of age) patients who were 
admitted to the 35-bed medical/surgical Department 
of Intensive Care of Erasme Hospital after OHCA or 
IHCA (excluding patients with CA occurring in the ICU) 
between January 2009 and January 2013. The local Insti-
tutional Review Board approved the study and waived 
the need for informed consent.
Routine post‑resuscitation care
A standardized institutional protocol is used in all post-
cardiac arrest patients (1). All comatose patients, irre-
spective of CA location and initial rhythm, are treated 
with targeted temperature management (TTM) for 24 h, 
with a target temperature of 32–34 °C. Cooling is started 
immediately after ICU admission with a combination of 
cold fluid bolus (20–30 ml/kg of a crystalloid solution in 
30  min) and a circulating water blanket device (Medi-
Therm II, Gaymar, USA). Body temperature is measured 
using invasive haemodynamic monitoring (PiCCO, Pul-
sion, Munich, Germany) when in place (need determined 
by attending physician depending on patient condition) 
or a rectal temperature probe. Analgo-sedation is pro-
vided using midazolam (0.03–0.1  mg/kg/h) and mor-
phine (0.1–0.3  mg/kg/h) infusions. Cisatracurium is 
administered to control shivering in the induction phase 
(as a bolus of 0.15 mg/kg) and, if needed, as a continuous 
infusion thereafter (1–3 mcg/kg/min). After 24 h of cool-
ing, rewarming (0.3–0.5 °C/h) is performed passively and 
sedation discontinued when body temperature reaches 
37 °C.
Patients are kept in a 30° semi-recumbent posi-
tion; ventilation is set to keep  PaCO2 between 35 and 
45 mmHg and  SpO2 > 94%. Transesophageal echocardi-
ography is routinely performed within the first 6–18  h 
after ICU admission. Blood glucose is kept between 
110 and 150  mg/dL and mean arterial pressure main-
tained  >  65–70  mm Hg using fluids, dobutamine and/
or noradrenaline. Intra-aortic balloon counterpulsa-
tion (IABP) or extracorporeal membrane oxygenation 
(ECMO) is used in cases of severe cardiogenic shock.
Neurological assessment and withdrawal of life support
After rewarming and discontinuation of sedation, 
repeated neurological examination and standard or 
continuous electroencephalography (EEG) together 
with somatosensory evoked potentials (SSEPs) at day 3 
are performed (“multimodal” approach). After the first 
72 h, a decision to withdraw life support may be taken in 
comatose patients based on: (a) bilateral absence of the 
N20 wave of SSEPs; (b) presence of status myoclonus 
(defined as continuous and generalized myoclonus per-
sisting for  ≥  30  min [11]) in combination with EEG 
abnormalities (generalized discharges or burst suppres-
sion); (c) refractory (i.e. resistant to two antiepileptic 
drugs and continuous intravenous sedative administra-
tion) status epilepticus occurring from a flat or burst sup-
pression background. The medical charts of patients were 
reviewed to classify deaths as “non-neurological” (i.e. 
persistent shock or multiple organ failure in the absence 
of neurological injury or before neurological prognosti-
cation could be assessed) or as neurological (i.e. severe 
anoxic brain injury) [12].
Data collection
We collected patient demographics, comorbidities and 
Utstein variables, including CA location, initial rhythm, 
bystander CPR and time to ROSC. After hospital admis-
sion, blood lactate concentrations are routinely meas-
ured with arterial blood gases, glucose and electrolytes 
every 3–4  h by point-of-care analysers (GEM Premier 
4000; Instrumentation Laboratory, Bedford, MA, USA). 
We recorded the initial lactate concentration, measured 
within 1 h after hospital admission, and values measured 
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at 6, 12, 24 and 48  h after admission, with a margin 
of ± 1 h. At the same time points, we also recorded blood 
gases, heart rate (HR) and MAP and calculated a sequen-
tial organ failure assessment (SOFA) score [13] from the 
ICU patient data monitoring system (Picis Critical Care 
Manager, Picis Inc., Wakefield, USA). The SOFA score 
was calculated excluding the neurological component 
because of the confounding effect of sedation. Shock was 
defined as a cardiovascular SOFA (cSOFA) of 3 or 4.
All available lactate measurements during the first 
48 h or until death (if the patient died within 48 h) were 
plotted to calculate the area under the curve  (AUC0-48). 
We report the highest value recorded during the first 
48  h as the “peak lactate”. The absolute decrease in lac-
tate concentrations from admission was calculated at 
6, 12 and 24  h, using the following formulas: [(lactate 
at 6  h—lactate on admission)/6] mEql/L, [(lactate at 
12  h—lactate on admission)/12] mEq/L and [(lactate at 
24  h—lactate on admission)/24] mEq/L. Similarly, the 
“relative” decrease in lactate concentrations was calcu-
lated as follows: [(lactate at 6  h—lactate on admission)/
lactate on admission ×  100]%, [(lactate at 12  h—lactate 
on admission)/lactate on admission  ×  100]% and [(lac-
tate at 24  h—lactate on admission)/lactate on admis-
sion × 100]% [8, 14].
Outcome assessment
Outcome was assessed by the neurological outcome at 
3  months, determined using the Cerebral Performance 
Category score (CPC; 1  =  no neurological disability, 
2  =  mild neurological disability, 3  =  severe neurologi-
cal impairment, 4 = vegetative state, 5 = death) [15]. The 
CPC was prospectively evaluated during follow-up visits 
or by telephone interview with the general practitioner. 
A favourable outcome was defined as a CPC 1 or 2 and 
poor outcome as CPC 3–5.
Statistical analysis
Statistical analyses were performed using IBM SPSS Sta-
tistics 21 for Macintosh. Descriptive statistics were com-
puted for all study variables. A Kolmogorov–Smirnov test 
was used, and histograms and normal quantile plots were 
examined to verify the normality of distribution of con-
tinuous variables. Data are presented as count (percent-
age), mean (± standard deviation) or median [25th–75th 
percentiles], as appropriate. Differences between groups 
were assessed using a Chi-square or Fisher’s exact test 
for categorical variables, as appropriate, and a T test or 
a Wilcoxon rank test for continuous variables. Data from 
repeated measures (lactate, HR, MAP, cSOFA on admis-
sion and at 6, 12, 24 and 48 h, thereafter) were analysed 
using a two-way ANOVA, or the Friedman ANOVA 
for data that were not normally distributed. Differences 
between groups for each time point were explored using 
a Mann–Whitney U test for nonparametric data. Asso-
ciation between continuous variables was evaluated 
using linear regression. Multivariable logistic regression 
was performed to identify factors independently associ-
ated with high blood lactate concentrations on admis-
sion. Multivariate binomial backward logistic regression 
was used to assess whether blood lactate on admission 
or decrease in lactate concentrations was independently 
correlated with favourable outcome. The discrimina-
tive ability of variables identified to predict neurological 
outcome by multivariate analysis was evaluated using 
receiver operating characteristic (ROC) curves with the 
corresponding AUC. Subgroup analyses included com-
parisons between IHCA and OHCA, patients with shock-
able and non-shockable rhythm and patients with shock 
(defined as cSOFA ≥ 3) and without shock on admission. 
A p < 0.05 was considered as statistically significant.
Results
General characteristics of the study cohort
Among 244 consecutive patients admitted to our ICU 
after CA, 236 were included in the study (Additional 
file  1: Figure S1). The mean age of our cohort was 
63 years; 155 (66%) patients were male and 137 (58%) had 
an OHCA; 162 (69%) patients had a poor neurological 
outcome at 3 months (Table 1).
Blood lactate concentrations and outcome
The median blood lactate concentration on admis-
sion was 4.3[2.0–8.5] mEq/L. Lactate concentrations 
were higher on admission (5.3[2.9–9.0] vs. 2.5[1.5–5.5], 
p  <  0.001) and at each time point thereafter in patients 
with poor than in those with favourable neurological 
outcome (Table 1 and Additional file 1: Figure S2). Peak 
lactate concentration (6.7[3.8–10.2] vs. 3.6[2.2–6.3], 
p < 0.001) and lactate  AUC0-48 (3.9[2.4–6] vs. 3.2[2.4–4.5] 
mEq/L*h, p  =  0.027) were also higher in patients with 
poor than in those with favourable neurological outcome. 
There were no differences in the relative changes in blood 
lactate concentrations at any time point between patients 
with poor and those with favourable neurological out-
comes (Table 1).
Blood lactate levels on admission were somewhat 
higher in patients who died from a non-neurological 
cause (n  =  72) than in those who died of neurological 
causes (n = 87), but the differences did not reach statis-
tical significance (6.5 [3.2–9.1 vs. 4.8 [2.4–9.4] mEq/L; 
p = 0.16). Changes in blood lactate concentrations from 
admission to 12 h were similar in these two groups (data 
not shown).
In multivariable analysis, high admission blood lactate 
concentration was associated with significantly higher 
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Table 1 Characteristics of study population according to neurological outcome at 3 months
Parameter All patients (236) CPC 1–2 (74) CPC 3–5 (162) p value
General
Age (years) 63 ± 15 59 ± 14 64 ± 16 0.03
Male, n (%) 155 (60%) 57 (77%) 98 (61%) 0.02
Comorbidities
COPD/asthma, n (%) 43 (18%) 15 (20%) 28 (17%) 0.59
Heart disease, n (%) 107 (46%) 40 (54%) 67 (42%) 0.09
Diabetes, n (%) 50 (21%) 21 (28%) 29 (18%) 0.08
Chronic renal failure, n (%) 38 (16%) 12 (16%) 26 (16%) 1
Liver cirrhosis, n (%) 14 (6%) 6 (8%) 8 (65%) 0.38
Immunosuppression, n (%) 28 (12%) 5 (7%) 23 (14%) 0.13
Cardiac arrest
OHCA, n (%) 137 (58%) 43 (58%) 94 (58%) 1
VF/VT, n (%) 100 (42%) 57 (77%) 43 (27%) <0.001
Bystander CPR, n (%) 136 (58%) 54 (73%) 82 (52%) 0.03
Time to ROSC (min) 19 ± 14 17 ± 13 20 ± 14 0.10
ABG
Lactate admission (mEq/L) 4.3 [2–8.5] 2.5 [1.5–5.5] 5.3 [2.9–9.0] <0.001
Lactate 6 h (mEq/L) 2.7 [1.6–5] 2.0 [1.3–2.9] 3.3 [1.8–5.9] <0.001
Lactate 12 h (mEq/L) 2.2 [1.4–4.2] 1.6 [1.2–2.3] 2.8 [1.6–5.3] <0.001
Lactate 24 h (mEq/L) 1.5 [1.1–2.8] 1.3 [1.0–1.7] 1.8 [1.3–3.2] <0.001
Lactate 48 h (mEq/L) 1.4 [1.0–2.0] 1.1 [0.8–1.7] 1.6 [1.1–2.5] 0.001
aDLC0‑6 (mEq/L*h) 0.2 [0–0.6] 0.1 [0–0.5] 0.2 [0–0.6] 0.16
aDLC0‑12 (mEq/L*h) 0.1 [0–0.3] 0.1 [0–0.2] 0.2 [0–0.4] 0.006
aDLC0‑24 (mEq/L*h) 0.1 [0–0.3] 0.1 [0–0.1] 0.1 [0–0.3] 0.008
rDLC0‑6 (%) 25 [−5 to 54] 24 [−8 to 56] 24 [−5 to 53] 0.98
rDLC0‑12 (%) 37 [2–62] 28 [−7 to 59] 40 [33–47] 0.08
rDLC0‑24 (%) 53 [18–71] 48 [25–68] 55 [17–77] 0.64
AUC0‑48, mEq/L*h 4.7 ± 4.2 3.74 ± 2.53 5.17 ± 4.72 0.016
Peak lactate, mEq/L 5 [3–9] 3.6 [2.2–6.3] 6.7 [3.8–10.2] <0.001
pH on admission 7.25 [7.16–7.36] 7.27 [7.18–7.37] 7.25 [7.15–7.34] 0.09
PaO2 on admission (mmHg) 121 [77–228] 143 [84–220] 118 [77–232] 0.54
PaCO2 on admission (mmHg) 42 ± 14 43 ± 12 42 ± 15 0.41
Haemodynamics
HR on admission (bpm) 89 ± 21 89 ± 19 88 ± 22 0.75
MAP on admission (mmHg) 90 ± 24 98 ± 23 88 ± 24 0.004
Vasopressors/inotropes on admission 130 (55%) 30 (40%) 100 (62%) 0.003
Vasopressors/inotropes at 6 h 139 (59%) 32 (43%) 107 (66%) 0.01
Vasopressors/inotropes at 12 h 150 (64%) 37 (50%) 113 (70%) 0.003
Vasopressors/inotropes at 24 h 129 (60%) 37 (50%) 92 (66%) 0.03
Vasopressors/inotropes at 48 h 131 (61%) 32 (43%) 99 (71%) <0.001
SOFA scores
SOFA score on admission 4 [2–7] 4 [2–5] 4 [2–8] 0.08
cSOFA admission 2 [0–4] 0 [0–3] 3 [0–4] 0.003
hSOFA admission 0 [0–0] 0 [0–0] 0 [0–1] 0.001
hSOFA maximum 0 [0–0] 0 [0–0] 0 [0–1] 0.001
Interventions
IABP, n (%) 18 (8%) 9 (12%) 9 (5.6%) 0.19
ECMO, n (%) 15 (6%) 2 (3%) 13 (8%) 0.15
CRRT, n (%) 32 (14%) 3 (4%) 29 (18%) 0.004
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odds of poor neurological outcome (OR 1.18[1.08–1.30], 
p < 0.001) (Table 2). Using an ROC curve, blood lactate 
on admission had a predictive accuracy of 0.69 (95% CI 
0.62–0.75) for poor neurological outcome (Additional 
file 1: Figure S3).
Subgroup analyses
Lactate concentrations were similar in IHCA and OHCA 
patients on admission and at subsequent time points 
(Table  3). In patients with IHCA, but not in those with 
OHCA, blood lactate concentrations were higher in 
patients with a poor neurological outcome than in those 
with a favourable outcome at all time points (Additional 
file 1: Table S1). Lactate concentrations on admission and 
at subsequent time points were similar in patients with 
shockable than those with non-shockable rhythms (Addi-
tional file 1: Table S2). Blood lactate concentrations were 
higher on admission and throughout the study period in 
patients with shock on admission than in those without 
(Additional file 1: Table S3).
Predictors of lactate concentrations and correlation 
with other haemodynamic variables
There was a weak correlation between blood lactate con-
centrations on admission and time to ROSC (r  =  0.29, 
p < 0.001) and MAP on admission (r = −0.39, p < 0.001, 
Fig. 1). There was also a significant correlation between 
initial blood lactate concentration and absolute decrease 
in lactate concentrations at 6 and 24 h (Additional file 1: 
Figure S4). In a linear regression model, the use of vaso-
pressors on admission, time to ROSC, initial  PaO2 and 
renal SOFA on admission were independently associated 
with high admission lactate levels (Table 4); however, the 
model explained only 32% of the variance.
Discussion
Patients with a poor neurological outcome after CA had 
higher lactate values on admission and over the first 
2  days than patients with a favourable outcome. Blood 
lactate concentration on admission remained a signifi-
cant predictor of poor outcome even after adjustment for 
major confounders. Nonetheless, the relative decrease in 
lactate at 6, 12 and 24 h was not related to neurological 
outcome. In a linear regression model, use of vasopres-
sors,  PaO2, time to ROSC and renal SOFA were inde-
pendently associated with high admission blood lactate 
concentration.
The pathophysiology of hyperlactataemia is complex 
and can involve tissue hypoperfusion, adrenergic hyper-
stimulation [16] and altered lactate clearance by the 
liver [17]. Interestingly, high lactate concentrations in 
our study were associated with renal dysfunction, which 
was probably a marker of organ failure [18] more than 
the kidney’s inability to clear lactate [16]. There was no 
association between lactate levels and the intensity of 
therapy (i.e. ECMO or IABP), although the number of 
treated patients was relatively limited. There was also no 
association of lactate on admission and hepatic dysfunc-
tion as assessed by the hepatic SOFA subscore. Moreo-
ver, increased  PaO2 values were predictive of high lactate 
concentration on admission. Recent studies have sug-
gested that very high  PaO2 values (>  300  mmHg) may 
aggravate post-anoxic brain injury [19]. However, a spe-
cific threshold for oxygen toxicity has not yet been iden-
tified in clinical practice and the mechanisms relating 
oxygen toxicity to lactate production need to be further 
evaluated in this setting.
A high blood lactate concentration on admission was 
significantly correlated with poor neurological outcome. 
Similarly, in a large cohort of 443 patients, Lee et  al. 
reported that a high blood lactate measured within 1 h of 
ROSC was correlated with CPC 3–5 at hospital discharge 
[7]. In 394 CA survivors enrolled over a 10-year period, 
CPC Cerebral Performance Category, CPC 1–2 favourable outcome, CPC 3–5 poor outcome, MAP mean arterial pressure, SOFA sequential organ failure assessment 
(without the neurological subscore), cSOFA cardiovascular SOFA score, ICU intensive care unit, LOS length of stay, HR heart rate, ABG arterial blood gas analysis, aDLC 
absolute decrease in lactate concentration over time expressed as mEq/L*h, rDLC relative decrease in lactate concentration over time expressed as %, AUC0-48 area 
under the curve of lactate concentrations for the first 48 h after admission, COPD chronic obstructive pulmonary disease, IABP intra-aortic balloon counterpulsation, 
ECMO extracorporeal membrane oxygenation, CRRT continuous renal replacement therapy, hSOFA hepatic SOFA subscore, VF/VT ventricular fibrillation/ventricular 
tachycardia, OHCA out-of-hospital cardiac arrest, CPR cardiopulmonary resuscitation, ROSC return of spontaneous circulation
Table 1 continued
Parameter All patients (236) CPC 1–2 (74) CPC 3–5 (162) p value
Outcomes
ICU LOS (days) 3 [1–6] 5 [3–11] 2 [1–4] <0.001
Neurological cause of death 87 (36%) – 87 (54%) <0.001
Table 2 Logistic regression analysis to  identify predictors 
of poor neurological outcome (CPC 3–5) at 3 months
OR odds ratio, CI confidence interval, CPR cardiopulmonary resuscitation
Parameter OR 95% CI p value
Bystander CPR 0.30 0.14–0.64 0.002
Shockable rhythm 0.11 0.05–0.23 <0.001
Lactate on admission, mEq/L 1.18 1.08–1.30 <0.001
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Kliegel et al. [20] found a significant correlation between 
lactate at baseline, 24 and 48  h and neurological out-
come. Moreover, blood lactate concentrations have been 
included, along with initial rhythm, estimated no-flow 
and low-flow intervals and creatinine levels, in a hospital 
admission predictive score for good neurological recov-
ery after successful resuscitation from OHCA [21].
A decrease in lactate concentrations over time is a reli-
able marker of effective treatment in critically ill patients 
with shock [22–25]. As expected, we found that the 
higher the lactate on admission, the greater the decrease 
over time [26]. However, there was no relationship 
between lactate decrease and neurological outcome. Our 
findings contrast with those of Donnino et  al. [14] who 
reported that lactate decrease at 6 and 12  h was more 
pronounced in survivors than in non-survivors, but no 
data on neurological recovery were available. Two stud-
ies have reported that the decrease in lactate at 12 h was 
an independent marker of good neurological outcome [8, 
9]. The differences between these studies and our results 
may be explained by a lower median lactate on admission 
in our study (4.3 mEq/L in our study vs. 6 to 15 mEq/L in 
[8, 9, 14]), which is probably explained by a shorter dura-
tion of CA in our cohort of patients.
Of note, we also reported data in patients with IHCA, 
whereas most previous studies included only OHCA 
patients. Only Karagiannis et al. [27], in a small group of 
28 patients after IHCA, described higher lactate concen-
trations at 6, 18 and 24  h after ROSC in non-survivors 
Table 3 Characteristics of  patients according to  arrest 
location (out of hospital [OHCA] vs. in hospital [IHCA])
Parameter OHCA (137) IHCA (99) P value
General
Age 61 ± 15 63 ± 15 040
Male 92 (67%) 64 (64%) 0.78
Comorbidities
COPD/asthma, n (%) 24 (17%) 19 (19%) 0.74
Heart disease, n (%) 62 (45%) 45 (45%) 1.00
Diabetes, n (%) 31 (23%) 19 (19%) 0.63
Chronic renal failure, 
n (%)
21 (15%) 17 (17%) 0.51
Liver cirrhosis, n (%) 6 (4%) 8 (8%) 0.27
Immunosuppression, 
n (%)
17 (12%) 11 (11%) 0.84
Cardiac arrest
VF/VT 65 (47%) 35 (35%) 0.086
Bystander CPR 57 (42%) 79 (80%) <0.001




4.3 [2.2–7.9] 4.8 [1.9–8.6] 0.81
Lactate 6 h (mEq/L) 2.7 [1.7–4.7] 2.7 [1.6–5.5] 0.51
Lactate 12 h (mEq/L) 2.2 [1.5–4.2] 2.3 [1.4–4.1] 0.78
Lactate 24 h (mEq/L) 1.5 [1.1–3.0] 1.4 [1.0–2.5] 0.605
Lactate 48 h (mEq/L) 1.4 [1.0–2.0] 1.4 [1.0–2.3] 0.415
aDLC0‑6 (mEq/L*h) .150 [−.03 to .583] .167 [0–.517] 0.88
aDLC0‑12 (mEq/L*h) 0.14 [0–0.3] 0.12 [0–0.3] 0.55
aDLC0‑24 (mEq/L*h) .075 [.004–.192] .073 [.018–.228] 0.469
rDLC0‑6 (%) 28 [−9 to 55] 22 [0–50] 0.75
rDLC0‑12 (%) 38 [0–64] 33 [7–61] 0.65
rDLC0‑24 (%) 51.6 [10.5–75.3] 56 [25.5–70.5] 0.558
AUC0‑48, mEq/L*h 4.6 ± 4 4.7 ± 4.4 0.901
Peak lactate, mEq/L 6.4 ± 3.8 6.9 ± 5.2 0.001
pH admission 7.25 [7.16–7.34] 7.27 [7.19–7.40] 0.038
PaO2 admission (mmHg) 124 [82–228] 116 [70–234] 0.289
PaCO2 admission 
(mmHg)
43.5 ± 14.8 40.4 ± 12.7 0.101
Haemodynamics
HR admission 87 ± 22 91 ± 19 0.120
MAP admission (mmHg) 96 ± 25 84 ± 20 <0.001
Vasopressors/inotropes 
admission
60 (44%) 70 (71%) <0.001
Vasopressors/inotropes 
6 h
67 (49%) 72 (73%) <0.001
Vasopressors/inotropes 
12 h
75 (55%) 75 (75%) 0.001
Vasopressors/inotropes 
24 h
66 (52%) 63 (73%) 0.002
Vasopressors/inotropes 
48 h
68 (53%) 63 (73%) 0.004
SOFA score
SOFA admission 3.5 [2–5] 5 [3–8] <0.001
cSOFA admission 0 [0–4] 3 [0–4] <0.001
Table 3 continued
Parameter OHCA (137) IHCA (99) P value
hSOFA baseline 0 [0–0] 0 [0–1] <0.001
hSOFA maximum 0 [0–0] 0 [0–1] 0.002
Interventions
IABP, n (%) 9 (7%) 9 (9%) 0.47
ECMO, n (%) 7 (5%) 8 (8%) 0.42
CRRT, n (%) 19 (14%) 13 (13%) 1
Outcomes
ICU LOS (days) 2 [1–6] 4 [1–7] 0.23
Neurological cause of 
death, n (%)
61 (44%) 26 (26%) 0.008
Poor outcome at 
3 months
94 (69%) 68 (69%) 0.711
MAP mean arterial pressure, SOFA sequential organ failure assessment (without 
the neurological subscore), cSOFA cardiovascular SOFA score, ICU intensive 
care unit, LOS length of stay, HR heart rate, aDLC absolute decrease in lactate 
concentration over time expressed as mEq/L*h, rDLC relative decrease in lactate 
concentration over time expressed as %; AUC0-48 area under the curve of lactate 
concentrations for the first 48 h since admission, COPD chronic obstructive 
pulmonary disease, IABP intra-aortic balloon counterpulsation, ECMO 
extracorporeal membrane oxygenation, CRRT continuous renal replacement 
therapy, hSOFA hepatic SOFA subscore, VF/VT ventricular fibrillation/ventricular 
tachycardia, OHCA out-of-hospital cardiac arrest, CPR cardiopulmonary 
resuscitation, ROSC return of spontaneous circulation
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than in survivors, and a significantly lower percentage 
decrease in lactate at 6 and 12 h in non-survivors. In our 
cohort, lactate levels were similar in IHCA and OHCA 
patients at all time points. This is of interest because 
IHCA is usually secondary to different aetiologies than 
OHCA and associated with severe pre-existing comor-
bidities, which may alter the generalizability of outcome 
predictors for OHCA to the IHCA setting. Blood lactate 
values were also similar regardless of the initial rhythm, 
despite the fact that patients with non-shockable rhythms 
are more likely to have prior hypoxia or hypotension and, 
in general, a longer time from arrest to CPR [28, 29]. This 
suggests that the prognostic value of lactate levels on 
admission is independent of these CA characteristics and 
applicable to a wide CA population.
Our study has some limitations. First, given the retro-
spective design, we could not reliably account for some 
variables that may have influenced lactate concentra-
tions, especially on admission, particularly CPR quality, 
total doses of adrenaline during CPR and fluid adminis-
tration or fluid balance. However, consistent manage-
ment in a single centre can reasonably exclude important 
differences in treatment strategies among patients. More-
over, we provided time to ROSC, but could not differenti-
ate between “no-flow” and “low-flow” times, which could 
further influence the initial lactate levels (e.g. prolonged 
“no-flow” times should be associated with higher lactate 
values). Second, we evaluated a limited cohort of patients, 
including a heterogeneous population of patients with 
IHCA and OHCA, which may limit the generalizability 
of our findings. Third, our model could account for only 
one-third of the variability in lactate concentrations on 
admission, indicating that other factors that we did not 
account for—e.g. no-flow period, total dose of adrena-
line given during CPR, vasopressors given during the 
ICU stay—may be involved in the pathophysiology of 
high lactate concentrations in this setting. Fourth, base-
line lactate concentration may be related to the quality of 
resuscitation during CA, whereas lactate concentration 
at 12 or 24 h may be related more to the quality of criti-
cal care provided. Although this statement sounds logi-
cal, we have almost no data in the literature to confirm 
this hypothesis and the retrospective nature of our study 
precludes any additional analysis. Furthermore, the inter-
pretation of baseline lactate could also be confounded 
by underlying conditions (e.g. sepsis) and/or aetiology of 
arrest (e.g. prolonged hypoxaemia before arrest). Fifth, 
lactate concentrations were available to the treating cli-
nicians; although lactate concentrations are not used as 
a marker of poor prognosis in this setting, we cannot 
exclude that persistently high lactate concentrations may 
have encouraged limitation of invasive therapies in some 
of these patients, thus raising the risk of “self-fulfilling 
prophecy”. Finally, we evaluated liver function using the 
hepatic SOFA subscore, which is based on total bilirubin 
levels. Hypoxic hepatitis, as observed after CA, is, how-
ever, defined as an elevation of aminotransferases; nev-
ertheless, the occurrence of hypoxic hepatitis is rare [30] 
Fig. 1 Panel A: Correlation between blood lactate concentration on 
admission and the time to return of spontaneous circulation (ROSC) 
(r = 0.29; p < 0.001). Panel B: Correlation between blood lactate con‑
centration on admission and the first recorded mean arterial pressure 
(MAP) (r = −0.39; p < 0.001)
Table 4 Linear regression analysis for  admission blood 
lactate
SOFA sequential organ failure assessment, ROSC return of spontaneous 
circulation
Parameter Coefficient p value
Renal SOFA 0.94 ± 0.23 <0.001
PaO2 on admission 0.006 ± 0.002 0.001
Time to ROSC (min) 0.067 ± 0.021 0.001
Vasopressors on admission 1.78 ± 0.62 0.004
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and generally occurs 1–2 days after CA, which would be 
of limited interest for interpretation of admission lactate 
levels.
Conclusions
Blood lactate concentrations in patients after CA were 
significantly higher in those with worse short- and long-
term outcomes. However, decrease in lactate over time 
was not correlated with outcome. Interpretation of high 
lactate concentrations in CA survivors is complex and 
multifactorial.
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